Tianjin Nankai Hecheng Technology Co., Ltd.
南开和成
Tianjin Nankai Hecheng Technology Co., Ltd. (南开和成) is a biotech materials company spun out of Nankai University's Institute of Polymer Chemistry, specializing in products for solid-phase synthesis of peptide and DNA drugs, separation and purification of peptides and proteins, and semi-synthesis of antibiotic drugs . The company completed a 200 million yuan Series B round led by Shenzhen Capital Group at the end of 2024, with BlueRun Ventures as its Series A backer . Its prior investors also include HLC, CMB International, and several state-linked funds . BlueRun Ventures, which has featured Nankai Hecheng at its biotech forums, counts it among its portfolio companies with "differentiated, internationalized, commercialized, and AI-crossover" characteristics in the biotech track .
AI-generated — may contain errors, please verify.
Coverage
Birds Fly Over the Harsh Winter | Monthly
Spring mountains within sight, the future there to climb.
Nankai Hecheng Completes 200 Million Yuan Series B Round | BlueRun Ventures Family
Accelerating Toward a Trillion-Yuan Future for the Polypeptide Industry
Beyond the Quadrant: Forging an Undefined Path | BlueRun Ventures 2024 Annual Fund Partners Meeting
Breaking Through a Mental Block
A New Drug King Is About to Be Crowned. Does Peptide Still Have Its Next Billion-Dollar Target? | BlueRun Ventures Viewpoint
You can only find things when you're not looking for them.
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
